Gene therapy for cancer treatment: past, present and future.
暂无分享,去创建一个
[1] A. Fattaey,et al. An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.
[2] C. Rudin,et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Schlom,et al. TRICOM vector based cancer vaccines. , 2006, Current pharmaceutical design.
[4] Sam S. Yoon,et al. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[5] D. Burgess,et al. DNA-based therapeutics and DNA delivery systems: A comprehensive review , 2005, The AAPS Journal.
[6] E. Jaffee,et al. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. , 2005, Cancer research.
[7] S. Rabkin,et al. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. , 2005, Cancer research.
[8] Leslie L Robison,et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E. Gehan,et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] W. Jarnagin,et al. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses , 2000, Journal of Gastrointestinal Surgery.
[11] J. Marshall,et al. Costimulatory molecules as adjuvants for immunotherapy. , 2006, Frontiers in bioscience : a journal and virtual library.
[12] A. Mackiewicz,et al. Cancer Immunotherapy Using Cells Modified with Cytokine Genes , 2022 .
[13] G. Demers,et al. Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy. , 2003, Cancer research.
[14] S. Ylä-Herttuala,et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[15] M. Hitt,et al. Transcriptionally targeted adenovirus vectors. , 2005, Current gene therapy.
[16] Hui Wang,et al. Recent advances in experimental molecular therapeutics for malignant gliomas. , 2004, Current medicinal chemistry. Anti-cancer agents.
[17] K. Tanabe,et al. Viral Oncolysis for Malignant Liver Tumors , 2003, Annals of Surgical Oncology.
[18] H. J. Baker,et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[19] Yuan Zhang,et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[20] M. Dobbelstein. Viruses in therapy--royal road or dead end? , 2003, Virus research.
[21] Zhao-hui Peng,et al. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. , 2005, Human gene therapy.
[22] R. Hruban,et al. A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas , 2007 .
[23] J. Nemunaitis. GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[24] F. Khuri,et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. , 2000, Cancer research.
[25] J. Nemunaitis,et al. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the baylor experience) , 2000, Annals of Surgical Oncology.
[26] J. Roth,et al. Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. , 2001, Seminars in oncology.
[27] T. Thompson. In situ gene therapy for prostate cancer. , 1999, Oncology research.
[28] R. Martuza,et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.
[29] A. Mackiewicz,et al. Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer , 2001, Expert opinion on biological therapy.
[30] F. Hall,et al. Nanotechnology blooms, at last (Review). , 2005, Oncology reports.
[31] Deborah Schrag,et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. , 2005, Journal of the National Cancer Institute.
[32] D. Brough,et al. TNFerade Biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene , 2002, Cancer Gene Therapy.
[33] L. Looi,et al. p53: an overview of over two decades of study. , 2001, The Malaysian journal of pathology.
[34] T. Kikuchi. Genetically modified dendritic cells for therapeutic immunity. , 2006, The Tohoku journal of experimental medicine.
[35] N. Gordon,et al. The challenges of bringing autologous HSP-based vaccines to commercial reality. , 2004, Methods.
[36] S. Paul,et al. Gene-based vaccines and immunotherapeutics , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[37] R. Mulligan,et al. The basic science of gene therapy. , 1993, Science.
[38] H. Kaufman,et al. Development of the PANVAC™-VF vaccine for pancreatic cancer , 2006, Expert review of vaccines.
[39] J. Prieto,et al. Gene therapy of liver diseases , 2004, Expert opinion on biological therapy.
[40] J. Gu,et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] R. Warren,et al. Intravascular adenoviral agents in cancer patients: Lessons from clinical trials , 2002, Cancer Gene Therapy.
[42] R. Weichselbaum,et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] D. Largaespada,et al. Sleeping beauty transposon-mediated gene therapy for prolonged expression. , 2005, Advances in genetics.
[44] J. Schlom,et al. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. , 2002, Cancer research.
[45] K. Delman,et al. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer , 2002, Cancer Gene Therapy.
[46] Yuan Zhang,et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[47] B. Sangro,et al. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. , 2003, Current gene therapy.
[48] K. Tanabe,et al. Viral oncolysis. , 2002, The oncologist.
[49] R. Figlin,et al. Phase I Trial of Antigen-Specific Gene Therapy Using a Recombinant Vaccinia Virus Encoding MUC-1 and IL-2 in MUC-1-Positive Patients With Advanced Prostate Cancer , 2004, Journal of immunotherapy.
[50] A. Schambach,et al. Tumor cells escape suicide gene therapy by genetic and epigenetic instability. , 2004, Blood.
[51] A. Armstrong,et al. Science, medicine, and the future: Cellular immunotherapy for cancer. , 2001, BMJ.
[52] B. Fox,et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer , 2006, Cancer Gene Therapy.
[53] Lawrence M Wein,et al. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. , 2003, Cancer research.
[54] R. Weichselbaum,et al. A Phase I Trial of TNFerade Biologic in Patients with Soft Tissue Sarcoma in the Extremities , 2004, Clinical Cancer Research.
[55] S. Yla-Herttuala,et al. Gene therapy for malignant glioma: current clinical status. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[56] F. McCormick,et al. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. , 2005, Cancer cell.
[57] H. Pandha,et al. Gene therapy for pancreatic cancer. , 1998, Italian journal of gastroenterology and hepatology.
[58] P. Scardino,et al. Intravesical oncolytic viral therapy using attenuated, replication‐competent, herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[59] N. Senzer,et al. TNFerade, an Adenovector Carrying the Transgene for Human Tumor Necrosis Factor α, for Patients With Advanced Solid Tumors: Surgical Experience and Long-Term Follow-Up , 2005, Annals of Surgical Oncology.
[60] Adam Bagg,et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.
[61] V. Margulis,et al. Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants. , 2005, Urology.
[62] D. Largaespada,et al. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[63] P. Claudio,et al. Gene therapy for lung cancer: practice and promise. , 2004, Annali italiani di chirurgia.
[64] F. Hall,et al. First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. , 2004, International journal of oncology.